Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
October 12 2021 - 8:30AM
InvestorsHub NewsWire
San Francisco, CA --
October 12, 2021 -- InvestorsHub NewsWire -- Oncology
Pharma Inc. (OTC:
ONPH) Oncology Pharma, Inc. (the “Company”) would like to
update investors on its progress. The Company is in the final
stages of engaging with a PCAOB Audit firm to support its effort to
meet one of the necessary steps to qualify for the
capital markets tier of the NASDAQ
exchange. The Company is committed to complete its
process and select a firm to conduct this audit within the next
couple of days.
In addition, the
Company is currently negotiating an extension to its licensing
agreement with Ribera Solutions (operating under the name of
“Connect2Med”) with ongoing discussions of further investments and
potentially taking on an equity position in the technology
directly. Connect2Med is a patient engagement and
retention platform designed to improve the clinical trial
experience for both patients and providers. With Connect2Med,
sponsors, CROs, and sites have a place for leads, or people in
their databases, to "live" in an online community. The platform
provides a private, secure space where people interested in or
recruited to clinical trials have a safe, closed community they can
join that provides trustworthy information and compassionate
connections to support them on their
journey. The company expects
to provide additional updates as they become
available.
ABOUT ONCOLOGY
PHARMA, INC.
ONCOLOGY PHARMA,
INC. (www.oncology-pharma.com) (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
ABOUT
Ribera Solutions, LLC (www.riberasolutions.com)
Ribera Solutions
(CA, USA) has developed Web based Connect2Med platform with iOS and
Android mobile Apps. Ribera's mission is to provide solutions for
solving challenging problems timely through simple, practical and
economical approaches.
FORWARD LOOKING
STATEMENTS
Certain of the
matters discussed in this announcement contain forward-looking
statements that involve material risks to and uncertainties in the
Company's business that may cause actual results to differ
materially from those anticipated by the statements made herein.
Such risks and uncertainties include risks related to licensing
arrangements and joint ventures, including the need to negotiate
the definitive agreements for the relationships; possible failure
to realize anticipated benefits of business relationships; and,
costs of providing funding to these business relationships. Other
risks and uncertainties relating to the Company include, among
other things, current negative operating cash flows and a need for
additional funding to finance our operating plan; the terms of any
further financing, which may be highly dilutive and may include
onerous terms; unexpected costs and operating deficits, and lower
than expected sales and revenues; uncertain willingness and ability
of customers to adopt new technologies and other factors that may
affect further market acceptance; adverse economic conditions;
adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or
retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as
well as our ability to possibly license from others patents and
patent applications necessary to develop products; the Company's
ability to implement its long range business plan for various
applications of its technology; the Company's ability to enter into
agreements with any necessary marketing and/or distribution
partners and with any strategic or joint venture partners; the
impact of competition; the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of the
Company's technology; management of growth; and, other risks and
uncertainties. This is not a solicitation to buy or sell securities
and does not purport to be an analysis of the Company's financial
position.
CONTACTS:
For additional
Information, please contact the Oncology Pharma
at:
One Sansome Street,
Suite 3500
San Francisco, CA
94104
Phone:
415-869-1038
Fax:
415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Oct 2023 to Oct 2024